Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 852

1.

Stopping 5-Aminosalicylate Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.

Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF.

Clin Gastroenterol Hepatol. 2019 Aug 13. pii: S1542-3565(19)30887-0. doi: 10.1016/j.cgh.2019.08.012. [Epub ahead of print]

PMID:
31419574
2.

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.

Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R.

J Crohns Colitis. 2019 Aug 12. pii: jjz131. doi: 10.1093/ecco-jcc/jjz131. [Epub ahead of print]

PMID:
31403666
3.

Viewpoint: Inflammatory bowel diseases among immigrants from low- to high-incidence countries: opportunities and considerations.

Agrawal M, Burisch J, Colombel JF, Shah SC.

J Crohns Colitis. 2019 Jul 30. pii: jjz139. doi: 10.1093/ecco-jcc/jjz139. [Epub ahead of print]

PMID:
31359034
4.

Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.

Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, Peyrin-Biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1673-1679.e1. doi: 10.1016/j.cgh.2018.10.032. Epub 2018 Oct 26. Review.

PMID:
31352970
5.

Changing epidemiology of immune-mediated inflammatory diseases in immigrants: A systematic review of population-based studies.

Agrawal M, Shah S, Patel A, Pinotti R, Colombel JF, Burisch J.

J Autoimmun. 2019 Jul 24:102303. doi: 10.1016/j.jaut.2019.07.002. [Epub ahead of print]

PMID:
31351784
6.

Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases.

Axelrad JE, Bazarbashi A, Zhou J, Castañeda D, Gujral A, Sperling D, Glass J, Agrawal M, Hong S, Lawlor G, Hudesman D, Chang S, Shah S, Yajnik V, Ananthakrishnan A, Khalili H, Colombel JF, Itzkowitz S; New York Crohn’s and Colitis Organization.

Clin Gastroenterol Hepatol. 2019 Jul 11. pii: S1542-3565(19)30735-9. doi: 10.1016/j.cgh.2019.06.042. [Epub ahead of print]

PMID:
31302306
7.

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR.

Gut. 2019 Jul 8. pii: gutjnl-2019-318256. doi: 10.1136/gutjnl-2019-318256. [Epub ahead of print]

8.

Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease.

Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein J, Feagan BG.

Gastroenterology. 2019 Jul 4. pii: S0016-5085(19)41080-9. doi: 10.1053/j.gastro.2019.06.038. [Epub ahead of print]

9.

Treating Inflammatory Bowel Disease With Diet: A Taste Test.

Sabino J, Lewis JD, Colombel JF.

Gastroenterology. 2019 Aug;157(2):295-297. doi: 10.1053/j.gastro.2019.06.027. Epub 2019 Jun 27. No abstract available.

PMID:
31254503
10.

Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.

Tepler A, Narula N, Peek RM Jr, Patel A, Edelson C, Colombel JF, Shah SC.

Aliment Pharmacol Ther. 2019 Jul;50(2):121-131. doi: 10.1111/apt.15306. Epub 2019 Jun 5. Review.

PMID:
31165513
11.

IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.

Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S.

J Crohns Colitis. 2019 Jun 3. pii: jjz110. doi: 10.1093/ecco-jcc/jjz110. [Epub ahead of print]

PMID:
31158271
12.

Challenges in IBD Research: Preclinical Human IBD Mechanisms.

Pizarro TT, Stappenbeck TS, Rieder F, Rosen MJ, Colombel JF, Donowitz M, Towne J, Mazmanian SK, Faith JJ, Hodin RA, Garrett WS, Fichera A, Poritz LS, Cortes CJ, Shtraizent N, Honig G, Snapper SB, Hurtado-Lorenzo A, Salzman NH, Chang EB.

Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S5-S12. doi: 10.1093/ibd/izz075.

PMID:
31095706
13.

Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?

Agrawal M, Colombel JF.

Gastrointest Endosc Clin N Am. 2019 Jul;29(3):421-436. doi: 10.1016/j.giec.2019.02.004. Epub 2019 Apr 6. Review.

PMID:
31078245
14.

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Leber A, Hontecillas R, Zoccoli-Rodriguez V, Colombel JF, Chauhan J, Ehrich M, Farinola N, Bassaganya-Riera J.

Inflamm Bowel Dis. 2019 May 11. pii: izz094. doi: 10.1093/ibd/izz094. [Epub ahead of print]

PMID:
31077582
15.

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.

Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS.

Inflamm Bowel Dis. 2019 May 3. pii: izz071. doi: 10.1093/ibd/izz071. [Epub ahead of print]

PMID:
31050734
16.

Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice.

Torres J, Hu J, Seki A, Eisele C, Nair N, Huang R, Tarassishin L, Jharap B, Cote-Daigneault J, Mao Q, Mogno I, Britton GJ, Uzzan M, Chen CL, Kornbluth A, George J, Legnani P, Maser E, Loudon H, Stone J, Dubinsky M, Faith JJ, Clemente JC, Mehandru S, Colombel JF, Peter I.

Gut. 2019 Apr 29. pii: gutjnl-2018-317855. doi: 10.1136/gutjnl-2018-317855. [Epub ahead of print]

PMID:
31036757
17.

Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics.

Porter CK, Riddle MS, Gutierrez RL, Princen F, Strauss R, Telesco SE, Torres J, Choung RS, Laird RM, Leon F, Colombel JF, Murray JA; PREDICTS study team.

Contemp Clin Trials Commun. 2019 Mar 26;14:100345. doi: 10.1016/j.conctc.2019.100345. eCollection 2019 Jun.

18.

The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Berg DR, Colombel JF, Ungaro R.

Inflamm Bowel Dis. 2019 Apr 1. pii: izz059. doi: 10.1093/ibd/izz059. [Epub ahead of print]

PMID:
30934053
19.

Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis.

Limketkai BN, Shah SC, Hirano I, Bellaguarda E, Colombel JF.

Gut. 2019 Mar 28. pii: gutjnl-2018-318074. doi: 10.1136/gutjnl-2018-318074. [Epub ahead of print]

PMID:
30923072
20.

Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.

Fenster M, Ungaro RC, Hirten R, Gallinger Z, Cohen L, Atreja A, Mehandru S, Colombel JF, Cohen BL.

Clin Gastroenterol Hepatol. 2019 Mar 22. pii: S1542-3565(19)30294-0. doi: 10.1016/j.cgh.2019.03.030. [Epub ahead of print]

PMID:
30910602
21.

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.

Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L.

Am J Gastroenterol. 2019 Jun;114(6):874-883. doi: 10.14309/ajg.0000000000000183.

22.

Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.

Hirten RP, Grinspan A, Fu SC, Luo Y, Suarez-Farinas M, Rowland J, Contijoch EJ, Mogno I, Yang N, Luong T, Labrias PR, Peter I, Cho JH, Sands BE, Colombel JF, Faith JJ, Clemente JC.

Inflamm Bowel Dis. 2019 May 4;25(6):969-979. doi: 10.1093/ibd/izy398.

PMID:
30852592
23.

Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?

Yzet C, Tse SS, Kayal M, Hirten R, Colombel JF.

Curr Pharm Des. 2019;25(1):57-63. doi: 10.2174/1381612825666190308102021.

PMID:
30848194
24.

Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data.

Philip G, Cornillie F, Adedokun JO, Melsheimer R, Rutgeerts P, Colombel JF, Marano C.

J Crohns Colitis. 2019 Mar 7. pii: jjz052. doi: 10.1093/ecco-jcc/jjz052. [Epub ahead of print]

PMID:
30847474
25.

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy.

Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W.

J Crohns Colitis. 2019 Feb 27. pii: jjz048. doi: 10.1093/ecco-jcc/jjz048. [Epub ahead of print]

PMID:
30809631
26.

Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials.

Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH.

BMJ Open. 2019 Jan 25;9(1):e024222. doi: 10.1136/bmjopen-2018-024222.

27.

Reply.

Hirten RP, Ghosh S, Colombel JF.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):796-797. doi: 10.1016/j.cgh.2018.08.056. No abstract available.

PMID:
30782323
28.

Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.

Shah SC, Khalili H, Chen CY, Ahn HS, Ng SC, Burisch J, Colombel JF.

Aliment Pharmacol Ther. 2019 Apr;49(7):904-911. doi: 10.1111/apt.15178. Epub 2019 Feb 17.

PMID:
30773656
29.

Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development.

King JA, Underwood FE, Panaccione N, Quan J, Windsor JW, Kotze PG, Ng SC, Ghosh S, Lakatos PL, Jess T, Panaccione R, Seow CH, Ben-Horin S, Burisch J, Colombel JF, Loftus EV Jr, Gearry R, Halfvarson J, Kaplan GG.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):287-295. doi: 10.1016/S2468-1253(19)30013-5. Epub 2019 Feb 12.

PMID:
30765267
30.

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF.

J Crohns Colitis. 2019 May 27;13(6):725-734. doi: 10.1093/ecco-jcc/jjy223.

31.

Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials.

Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W.

J Crohns Colitis. 2019 Feb 6. doi: 10.1093/ecco-jcc/jjz031. [Epub ahead of print]

PMID:
30726897
32.

Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity.

Harpaz N, Ballentine S, Colombel JF, E Sands B, Ko HM.

Gut. 2019 Feb 5. pii: gutjnl-2018-318137. doi: 10.1136/gutjnl-2018-318137. [Epub ahead of print] No abstract available.

PMID:
30723105
33.

Reply.

Colombel JF, Shin A, Gibson PR.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):573-574. doi: 10.1016/j.cgh.2018.08.073. No abstract available.

PMID:
30678842
34.

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T.

Ann Rheum Dis. 2019 Apr;78(4):473-479. doi: 10.1136/annrheumdis-2018-214273. Epub 2019 Jan 23.

35.

Gut microbiota density influences host physiology and is shaped by host and microbial factors.

Contijoch EJ, Britton GJ, Yang C, Mogno I, Li Z, Ng R, Llewellyn SR, Hira S, Johnson C, Rabinowitz KM, Barkan R, Dotan I, Hirten RP, Fu SC, Luo Y, Yang N, Luong T, Labrias PR, Lira S, Peter I, Grinspan A, Clemente JC, Kosoy R, Kim-Schulze S, Qin X, Castillo A, Hurley A, Atreja A, Rogers J, Fasihuddin F, Saliaj M, Nolan A, Reyes-Mercedes P, Rodriguez C, Aly S, Santa-Cruz K, Peters L, Suárez-Fariñas M, Huang R, Hao K, Zhu J, Zhang B, Losic B, Irizar H, Song WM, Di Narzo A, Wang W, Cohen BL, DiMaio C, Greenwald D, Itzkowitz S, Lucas A, Marion J, Maser E, Ungaro R, Naymagon S, Novak J, Shah B, Ullman T, Rubin P, George J, Legnani P, Telesco SE, Friedman JR, Brodmerkel C, Plevy S, Cho JH, Colombel JF, Schadt EE, Argmann C, Dubinsky M, Kasarskis A, Sands B, Faith JJ.

Elife. 2019 Jan 22;8. pii: e40553. doi: 10.7554/eLife.40553.

36.

Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.

Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E, Lawlor G, Sultan K, Lukin D, Colombel JF, Ungaro RC.

Aliment Pharmacol Ther. 2019 Mar;49(5):564-571. doi: 10.1111/apt.15107. Epub 2019 Jan 20.

PMID:
30663075
37.

Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis.

Shah SC, Tepler A, Peek RM Jr, Colombel JF, Hirano I, Narula N.

Clin Gastroenterol Hepatol. 2019 Jan 16. pii: S1542-3565(19)30033-3. doi: 10.1016/j.cgh.2019.01.013. [Epub ahead of print] Review.

PMID:
30659992
38.

Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice.

Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, Li Z, Mortha A, Merad M, Das A, Gevers D, McGovern DPB, Singh N, Braun J, Jacobs JP, Clemente JC, Grinspan A, Sands BE, Colombel JF, Dubinsky MC, Faith JJ.

Immunity. 2019 Jan 15;50(1):212-224.e4. doi: 10.1016/j.immuni.2018.12.015.

39.

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R.

Clin Gastroenterol Hepatol. 2019 Jan 6. pii: S1542-3565(19)30013-8. doi: 10.1016/j.cgh.2018.12.040. [Epub ahead of print]

40.

No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases.

Mahmoud R, Shah SC, Ten Hove JR, Torres J, Mooiweer E, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH; Dutch Initiative on Crohn and Colitis.

Gastroenterology. 2019 Apr;156(5):1333-1344.e3. doi: 10.1053/j.gastro.2018.11.067. Epub 2018 Dec 7.

PMID:
30529584
41.

Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis.

Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Lin E, Borody TJ, Wilkins MR, Colombel JF, Mitchell HM, Kaakoush NO.

Gastroenterology. 2019 Apr;156(5):1440-1454.e2. doi: 10.1053/j.gastro.2018.12.001. Epub 2018 Dec 6.

PMID:
30529583
42.

Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems.

Pauwen NY, Louis E, Siegel C, Colombel JF, Macq J.

J Crohns Colitis. 2018 Nov 28;12(12):1499-1504. doi: 10.1093/ecco-jcc/jjy128. Review.

PMID:
30496446
43.

Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.

Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T.

Gut. 2019 Jun;68(6):977-984. doi: 10.1136/gutjnl-2018-317021. Epub 2018 Nov 12.

PMID:
30420398
44.

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Dec;113(12):696. doi: 10.1038/s41395-018-0401-4.

45.

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.

Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K.

J Crohns Colitis. 2019 Feb 1;13(2):172-181. doi: 10.1093/ecco-jcc/jjy149.

46.

Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.

Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaau4711. doi: 10.1126/scitranslmed.aau4711.

47.

The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.

Borman ZA, Côté-Daigneault J, Colombel JF.

Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101-1108. doi: 10.1080/17474124.2018.1530983. Epub 2018 Oct 10. Review.

PMID:
30277409
48.

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.

Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1533-1540.e2. doi: 10.1016/j.cgh.2018.09.035. Epub 2018 Sep 27.

49.

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.

Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1525-1532.e1. doi: 10.1016/j.cgh.2018.09.033. Epub 2018 Sep 26.

50.

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.

Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT.

J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125.

Supplemental Content

Loading ...
Support Center